Study: Boceprevir increases hepatitis C patients' response rate

08/9/2010 | HealthDay News

Merck & Co.'s boceprevir appeared to improve viral response in hepatitis C patients when added to the standard combination treatment of pegylated interferon and ribavirin during a company-funded Phase II study. "Boceprevir, in combination with pegylated interferon and ribavirin, achieves high [virological response] rates with 28 weeks of therapy in most patients, and is safe and effective for use up to 48 weeks in the few patients who benefit from longer duration of therapy," according to the research.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT